{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:18:17Z","timestamp":1761898697245,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clinre.2022.102000","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T12:07:42Z","timestamp":1659528462000},"page":"102000","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute myeloid leukaemia following direct acting antiviral drugs in HCV-infected patients: A 10 years\u2019 retrospective single-center study"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2291-559X","authenticated-orcid":false,"given":"Carole","family":"Scheifer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Luckina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9n\u00e9dicte","family":"Lebrun-Vignes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdoul-Aziz","family":"Diop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Damais-Thabut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Roos-Weil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Dechartres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Lebray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"unstructured":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. (2468-1253 (Electronic)).","key":"10.1016\/j.clinre.2022.102000_bib0001"},{"issue":"Suppl 2","key":"10.1016\/j.clinre.2022.102000_bib0002","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1471-2334-12-S2-S2","article-title":"Chronic HCV infection: epidemiological and clinical relevance","volume":"12","author":"Zaltron","year":"2012","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1016\/j.clinre.2022.102000_bib0003","first-page":"192","article-title":"Mortality Rates in Patients With Chronic Hepatitis C and Cirrhosis Compared With the General Population: a Danish Cohort Study","volume":"215","author":"Hallager","year":"2017","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.clinre.2022.102000_bib0004","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"Perz","year":"2006","journal-title":"J Hepatol"},{"unstructured":"World Health Organization. Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: updated Version. 2016.","key":"10.1016\/j.clinre.2022.102000_bib0005"},{"key":"10.1016\/j.clinre.2022.102000_bib0006","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.pharmthera.2017.10.009","article-title":"Direct antiviral agents (DAAs) - a new age in the treatment of hepatitis C virus infection","volume":"183","author":"Spengler","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinre.2022.102000_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/liv.14119","article-title":"Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: a systematic review and meta-analysis","author":"Masarone","year":"2019","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.clinre.2022.102000_bib0008","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2022.102000_bib0009","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s10637-019-00870-9","article-title":"The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment","volume":"38","author":"Kuo","year":"2020","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.clinre.2022.102000_bib0010","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J Hepatol"},{"issue":"18","key":"10.1016\/j.clinre.2022.102000_bib0011","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.297.18.2010","article-title":"Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus","volume":"297","author":"Giordano","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.clinre.2022.102000_bib0012","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1053\/j.gastro.2006.09.019","article-title":"Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH","volume":"131","author":"Nieters","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2022.102000_bib0013","series-title":"Hematopathology","first-page":"279","article-title":"Chapter 13 - acute Leukaemias of Ambiguous Lineage","author":"Naeim","year":"2008"},{"key":"10.1016\/j.clinre.2022.102000_bib0014","article-title":"Aggressive recurrence of Non-Hodgkin's Lymphoma after successful clearance of hepatitis C virus with direct acting antivirals","author":"Samonakis","year":"2019","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clinre.2022.102000_bib0015","doi-asserted-by":"crossref","first-page":"e402","DOI":"10.1038\/bcj.2016.16","article-title":"Development of highly aggressive mantle cell lymphoma after sofosbuvir treatment of hepatitis C","volume":"6","author":"Lin","year":"2016","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clinre.2022.102000_bib0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000484653","article-title":"Primary Liver Diffuse Large B-Cell Lymphoma following Complete Response for Hepatitis C Infection after Direct Antiviral Therapy","volume":"139","author":"Andrade","year":"2018","journal-title":"Acta Haematol"},{"issue":"5","key":"10.1016\/j.clinre.2022.102000_bib0017","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/jvh.12843","article-title":"HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: the game is not over after HCV eradication","volume":"25","author":"Rodr\u00edguez de Santiago","year":"2018","journal-title":"J Viral Hepat"},{"issue":"2","key":"10.1016\/j.clinre.2022.102000_bib0018","first-page":"177","article-title":"Recurrence of malignant lymphoma immediately after treatment for hepatitis C virus using direct-acting antivirals","volume":"116","author":"Iwane","year":"2019","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"10.1016\/j.clinre.2022.102000_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2021.06.014","article-title":"Risk of Non-Hodgkin's Lymphoma in HCV Patients in the United States Between 2013 and 2020: a Population-Based Study","author":"Alkrekshi","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clinre.2022.102000_bib0020","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2010-06-275818","article-title":"Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities","volume":"117","author":"Marcucci","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clinre.2022.102000_bib0021","first-page":"1","article-title":"Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: a case report and literature review","volume":"13","author":"Sakai","year":"2020","journal-title":"Mol Clin Oncol"},{"issue":"21","key":"10.1016\/j.clinre.2022.102000_bib0022","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","article-title":"Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection","volume":"128","author":"Arcaini","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clinre.2022.102000_bib0023","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s12029-019-00293-y","article-title":"Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection","volume":"51","author":"Khoury","year":"2020","journal-title":"J Gastrointest Cancer"},{"issue":"11","key":"10.1016\/j.clinre.2022.102000_bib0024","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/apt.15240","article-title":"The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection","volume":"49","author":"El-Serag","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2022.102000_bib0025","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1158\/1055-9965.EPI-21-0742","article-title":"Cancer in people with and without hepatitis C virus infection: comparison of risk before and after introduction of direct-acting antivirals","volume":"30","author":"Lam","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.clinre.2022.102000_bib0026","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2016.12.019","article-title":"Increased peripheral CD4+regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C","volume":"66","author":"Langhans","year":"2017","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2022.102000_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167934","article-title":"DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: a Rationale for Tumor Risk during Anti-HCV Treatment","volume":"11","author":"Villani","year":"2016","journal-title":"PLoS ONE"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740122001346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:32:37Z","timestamp":1761895957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740122001346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2210740122001346"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2022.102000","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute myeloid leukaemia following direct acting antiviral drugs in HCV-infected patients: A 10 years\u2019 retrospective single-center study","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2022.102000","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102000"}}